Primary Effusion Lymphoma Secretome Analysis Reveals Novel Candidate Biomarkers with Potential Pathogenetic Significance

Primary effusion lymphoma (PEL) is a rare B-cell neoplasm in which tumor cells are consistently infected by Kaposi's sarcoma associated herpesvirus and usually grow in body cavities without tumor mass formation. To detect new proteins related to pathogenesis, four established cell lines from PEL (CRO-AP2, CRO-AP3, CRO-AP5, and CRO-AP6) were characterized by proteomics analysis of the secretome. The secretomes were analyzed using two complementary mass spectrometry platforms: Liquid chromatography mass spectrometry and matrix-assisted Laser desorption/ionization time-of-flight based approaches. Among 266 proteins identified from the proteomics analysis, 139 were considered as predicted secreted. Twenty proteins were specifically secreted by PEL cell Lines after comparison with secretomes of human cell lines representative of diverse solid tumors and Leukemias. More important, 27 additional proteins were shared by all CRO-AP PEL cell lines. The presence of these proteins was confirmed by INC in CRO-AP cell Lines and in six other PEL cell lines, four PEL clinical samples, and three extracavitary Kaposi's sarcoma associated herpesvirus positive solid Lymphomas included for comparative analysis. Functional classification showed that PEL cell secretomes were enriched in proteins specifically involved in inflammation/immune response, growth/cell cycle, and mRNA processing, in addition to structural/matrix proteins and proteins with enzymatic activity.